Company news from 09/09 News Brief

Share this article:

Eyetech Pharmaceuticals, whose only product is a treatment for age-related macular degeneration, agreed to sell itself to OSI Pharmaceuticals for about $935 million. OSI markets the Tarceva cancer drug, and Chief Executive Collin Goddard said the purchase would allow it to expand into the eye-treatment market.

GlaxoSmithKline said this week it would pay $1.4 billion to acquire ID Biomedical, a Canadian vaccine maker. The agreement does not preclude another company from making a higher offer, but Glaxo would have the right to match such an offer.

Fission Communications has created a new division, Fission Meeting Management Services, to help clients plan and execute special events for all types of organizations. Blanca Diaz, senior director of meeting services, will head the unit.

Palio Communications earned a bronze award at the 2005 International Awards of Excellence (IN-AWE) in the category of journal advertising and self-promotion. The industry advertising award, bestowed by the Medical Marketing Association (MMA), recognized the agency's "Never Be Forgotten" print ad campaign.

InChord Communications and Italian ad firm DWA have partnered to create a new agency to focus on healthcare marketing clients in Italy. DWA Health will be based in Milan with an office in Turin.

Japanese clinical research organization Shin Nippon Biomedical Laboratories  has opened a facility in the University of Maryland, Baltimore's BioPark. The 40,000-square-foot site focuses on Phase I/IIa clinical trials, particularly safety and tolerability testing, for pharmaceutical, biotechnology and medical device companies. Capabilities include the areas of CNS, cardiovascular, respiratory, and gastrointestinal.

Sanofi-Aventis Group has extended a research collaboration between its Aventis Pharmaceuticals  unit and ImmunoGen for a fourth year, committing $18.2 million in research support that will start next September. The funding is in addition to research support committed for the three years ending August 31, 2006. The collaboration aims to discover, develop, and commercialize novel antibody-based anticancer products.

Ferndale Laboratories has created Biopelle, a new division devoted to aesthetic medicine.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...